|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||||||
| Cash | ||||||||||||
| Receivables, net | ||||||||||||
| Other receivables | ||||||||||||
| Prepaids and deposits | ||||||||||||
| Short-term loan receivable | ||||||||||||
| Inventory | ||||||||||||
| Investment in securities- current | ||||||||||||
| Assets held for sale | ||||||||||||
| Total Current Assets | ||||||||||||
| Deposit | ||||||||||||
| Operating lease right-of-use-assets | ||||||||||||
| Investment in securities-noncurrent | ||||||||||||
| Property and equipment, net | ||||||||||||
| Intangibles, net | ||||||||||||
| Assets held for sale – non-current | ||||||||||||
| Goodwill | ||||||||||||
| TOTAL ASSETS | ||||||||||||
| Current Liabilities | ||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||
| Customer deposits | ||||||||||||
| Due to related parties | ||||||||||||
| Related Party | ||||||||||||
| Total due to related parties | ||||||||||||
| Current portion of consideration payable | ||||||||||||
| Current portion of operating lease liability | ||||||||||||
| Current portion of equipment financing payable | ||||||||||||
| Derivative liabilities | ||||||||||||
| Current portion of promissory notes payable | ||||||||||||
| Convertible debt | ||||||||||||
| Liabilities held for sale | ||||||||||||
| Total Current Liabilities | ||||||||||||
| Consideration payable | ||||||||||||
| Promissory notes payable | ||||||||||||
| Operating lease liability | ||||||||||||
| Equipment financing payable | ||||||||||||
| Deferred tax liabilities | ||||||||||||
| Consideration payable | ||||||||||||
| Liabilities held for sale – non-current | ||||||||||||
| TOTAL LIABILITIES | ||||||||||||
| EQUITY | ||||||||||||
| Preferred stock value | ||||||||||||
| Series Seed 1 Preferred Stock | ||||||||||||
| Series Seed 2 Preferred Stock | ||||||||||||
| Series A Preferred Stock | ||||||||||||
| Series B Preferred Stock | ||||||||||||
| Common stock, $0.0001 par value, 1,000,000,000 shares authorized; 6,153,780 and 80,699 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively (1) | ||||||||||||
| Additional paid-in capital | ||||||||||||
| Accumulated other comprehensive income | ||||||||||||
| Accumulated deficit | ||||||||||||
| TOTAL EQUITY | ||||||||||||
| TOTAL LIABILITIES AND EQUITY |
Loading...
